Finance

Beta
Lists
TVRD:NASDAQ
Tvardi Therapeutics Inc
$1.95
+2.63%
(+0.050) 1D
$1.89
-3.08% (-0.060)
Pre-market
Closed: Jul 1, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TVRD...
Open
$1.86
High
$2.03
Low
$1.80
Mkt. cap
18.29M
Avg. vol.
277.93K
Volume
1.55K
52-wk high
$43.65
52-wk low
$1.50
EPS
-$1.60
Beta
0.33
Shares outstanding
9.38M
No. of employees
12
Open
$1.86
High
$2.03
Low
$1.80
Mkt. cap
18.29M
Avg. vol.
277.93K
Volume
1.55K
52-wk high
$43.65
52-wk low
$1.50
EPS
-$1.60
Beta
0.33
Shares outstanding
9.38M
No. of employees
12
News stories
From sources across the web
About Tvardi Therapeutics Inc
CEO-
Employees12
Founded2017
HeadquartersSugar Land, Texas, United States
SectorPharmaceutical industry
Websitetvarditherapeutics.com
Analyst ratings
Based on 6 analysts giving stock ratings to TVRD in the past 3 months
Buy
Buy
4
Hold
1
Sell
1
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for TVRD in the last 3 months.
Highest
Current $1.95
$15.00 (+669.23%)
Average
$9.80 (+402.56%)
Lowest
$3.00 (+53.85%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sara Nik
H.C. Wainwright
Buy
Initiated
$9.00
+361.5%
06/08/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
$12.00
+515.4%
05/12/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
$10.00
+412.8%
05/11/2026
Unknown Analyst
Cantor Fitzgerald
Hold
Maintained
-
-
05/11/2026
Etzer Darout
Barclays
Sell
Reiterated
$3.00
+53.8%
05/08/2026
Julian Harrison
BTIG
Buy
Maintained
$15.00
+669.2%
05/08/2026
Jay Olson
Oppenheimer
Buy
Reiterated
$10.00
+412.8%
04/02/2026
Yasmeen Rahimi
Piper Sandler
Hold
Maintained
$3.00
+53.8%
04/01/2026
Steven Seedhouse
Cantor Fitzgerald
Hold
Maintained
-
-
04/01/2026
Christopher Liu
Lucid Capital
Buy
Upgraded
$6.00
+207.7%
02/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
5.81M
3.60M
5.49M
4.91M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.06M
2.34M
2.10M
2.14M
Operating expense
8.87M
5.94M
7.59M
7.05M
Total operating expenses
8.87M
5.94M
7.59M
7.05M
Operating income
-8.87M
-5.94M
-7.59M
-7.05M
Other non operating income
12.66M
-
-
-
EBT including unusual items
4.17M
-5.53M
-7.28M
-6.80M
EBT excluding unusual items
4.17M
-5.53M
-7.28M
-6.80M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
4.17M
-5.53M
-7.28M
-6.80M
Net profit margin
-
-
-
-
Earnings per share
0.51
-0.59
-0.78
-0.73
Interest and investment income
377.00K
411.00K
312.00K
247.00K
Interest expense
-
-
-
-
Net interest expenses
377.00K
411.00K
312.00K
247.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-8.85M
-5.91M
-7.56M
-7.03M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer